-
公开(公告)号：US20180369374A1
公开(公告)日：2018-12-27
申请号：US15996146
申请日：2018-06-01
Applicant: ModernaTX, Inc.
Inventor： Joshua P. FREDERICK , Susannah HEWITT , Ailin BAI , Stephen G. HOGE , Vladimir PRESNYAK , Iain MCFADYEN , Kerry BENENATO , Ellalahewage Sathyajith KUMARASINGHE
IPC: A61K39/395 , A61K39/00
CPC classification number: A61K39/39558 , A61K31/713 , A61K39/0011 , A61K39/39 , A61K45/06 , A61K2039/505 , A61K2039/53 , A61K2039/585 , A61P35/00 , C07K14/54 , C07K14/5434 , C07K14/5443 , C07K14/705 , C07K14/70503 , C07K14/70532 , C07K14/70575 , C07K14/70596 , C07K16/2818 , C07K2317/76 , C07K2319/30 , C07K2319/32 , A61K2300/00
Abstract: The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.
-
公开(公告)号：US20230026381A1
公开(公告)日：2023-01-26
申请号：US17930369
申请日：2022-09-07
Applicant: ModernaTX, Inc.
Inventor： Joshua FREDERICK , Ailin BAI , Vladimir PRESNYAK , Stephen HOGE , Kerry BENENATO , Iain MCFADYEN , Ellalahewage Sathyajith KUMARASINGHE , Susannah HEWITT
IPC: A61K9/51 , A61K48/00 , A61K38/17 , A61K38/20 , A61K9/00 , A61K39/39 , A61K45/06 , A61K9/127 , C07K14/54 , C07K14/545 , C07K14/705 , A61K31/7088 , A61K31/7115 , A61P35/00 , A61K39/395
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
-
公开(公告)号：US20220265774A1
公开(公告)日：2022-08-25
申请号：US17721583
申请日：2022-04-15
Applicant: ModernaTX, Inc.
Inventor： Joshua FREDERICK , Susannah HEWITT , Ailin BAI , Stephen HOGE , Vladimir PRESNYAK , Iain James MCFADYEN , Kerry BENENATO , Ellalahewage Sathyajith KUMARASINGHE
IPC: A61K38/20 , A61K9/51 , C07K14/54 , A61K31/7088 , A61K31/7115 , A61K48/00 , C12N15/62 , A61P35/00 , A61K9/00
Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.
-
公开(公告)号：US20190382774A1
公开(公告)日：2019-12-19
申请号：US16300223
申请日：2017-05-18
Applicant: ModernaTX, Inc.
Inventor： Stephen G. HOGE , Kerry BENENATO , Vladimir PRESNYAK , Iain MCFADYEN , Ellalahewage Sathyajith KUMARASINGHE , Staci SABNIS , William BUTCHER
IPC: C12N15/67 , A61K31/7115 , A61K48/00
Abstract: The invention related to polyribonucleotides comprising an open reading frame of linked nucleosides encoding a polypeptide of interest (e.g., a therapeutic polypeptide), isoforms thereof, functional fragments thereof, and fusion proteins comprising the polypeptide. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the invention provides sequence-optimized polyribonucleotides comprising nucleotides encoding the sequence of the polypeptide of interest, or sequence having high sequence identity with those sequence optimized polyribonucleotides.
-
15.发明申请公开(公告)号：US20190298657A1
公开(公告)日：2019-10-03
申请号：US16302298
申请日：2017-05-18
Applicant: MODERNATX, INC.
Inventor： Paolo MARTINI , Stephen HOGE , Kerry BENENATO , Vladimir PRESNYAK , Iain McFADYEN , Ellalahewage Sathyajith KUMARASINGHE , Evan Lockwood RACHLIN , Staci SABNIS
Abstract: The invention relates to mRNA therapy for the treatment of VLCADD. mRNAs for use in the invention, when administered in vivo, encode human acyl-CoA dehydrogenase, very longchain (ACADVL), isoforms thereof, functional fragments thereof, and fusion proteins comprising ACADVL. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of ACADVL expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient ACADVL activity in subjects, namely acylcarnitine and acylcarnitine metabolites.
-
Patent Agency Ranking
公开(公告)号：US20190105280A1
公开(公告)日：2019-04-11
申请号：US16219418
申请日：2018-12-13
Applicant: ModernaTX, Inc.
Inventor： Joshua FREDERICK , Ailin BAI , Vladimir PRESNYAK , Stephen HOGE , Kerry BENENATO , Iain MCFADYEN , Ellalahewage Sathyajith KUMARASINGHE , Susannah HEWITT
IPC: A61K9/51 , A61K9/00 , C07K14/54 , A61K38/17 , A61K38/20 , C07K14/705 , A61P35/00 , A61K39/395
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
-
公开(公告)号：US20180318229A1
公开(公告)日：2018-11-08
申请号：US15995889
申请日：2018-06-01
Applicant: ModernaTX, Inc.
Inventor： Joshua FREDERICK , Ailin BAI , Vladimir PRESNYAK , Stephen HOGE , Kerry BENENATO , Iain MCFADYEN , Ellalahewage Sathyajith KUMARASINGHE , Susannah HEWITT
IPC: A61K9/51 , A61P35/00 , A61K38/20 , A61K38/17 , C07K14/54 , C07K14/705 , A61K39/395 , A61K9/00
CPC classification number: A61K9/5123 , A61K9/00 , A61K9/0019 , A61K9/1272 , A61K9/5146 , A61K38/177 , A61K38/1774 , A61K38/20 , A61K38/2006 , A61K38/208 , A61K38/2086 , A61K39/39 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/51 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/585 , A61P35/00 , B82Y5/00 , C07K14/54 , C07K14/5434 , C07K14/5443 , C07K14/5446 , C07K14/545 , C07K14/70575 , C07K2319/00 , C12N15/88 , A61K2300/00
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
-
公开(公告)号：US20230346928A1
公开(公告)日：2023-11-02
申请号：US18190453
申请日：2023-03-27
Applicant: ModernaTX, Inc.
Inventor： Joshua P. FREDERICK , Susannah HEWITT , Ailin BAI , Stephen G. HOGE , Vladimir PRESNYAK , Iain MCFADYEN , Kerry BENENATO , Ellalahewage Sathyajith KUMARASINGHE
IPC: A61K39/395 , C07K14/54 , C07K14/705 , C07K16/28 , A61K39/39 , A61K45/06 , A61K31/713 , A61K48/00 , A61K39/00
CPC classification number: A61K39/39558 , C07K14/54 , C07K14/5434 , C07K14/5443 , C07K14/705 , C07K14/70503 , C07K14/70532 , C07K14/70575 , C07K14/70596 , C07K16/2818 , A61K39/39 , A61K45/06 , A61K31/713 , A61K48/005 , A61K39/0011 , A61K2039/505 , A61K2039/53 , C07K2317/76 , C07K2319/30 , C07K2319/32 , A61K2039/585 , A61K2039/51 , A61P35/00
Abstract: The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.
-
公开(公告)号：US20220251577A1
公开(公告)日：2022-08-11
申请号：US17618776
申请日：2020-06-24
Applicant: ModernaTX, Inc.
Inventor： Alicia BICKNELL , Vladimir PRESNYAK , Caroline KÖHRER
IPC: C12N15/67 , A61K31/7105
Abstract: The present disclosure provides messenger RNAs (mRNAs) with alterations which provide increased endonuclease resistance to the mRNA and methods and uses thereof.
-
公开(公告)号：US20210299221A1
公开(公告)日：2021-09-30
申请号：US17308686
申请日：2021-05-05
Applicant: ModernaTX, Inc.
Inventor： Joshua FREDERICK , Susannah HEWITT , Ailin BAI , Stephen HOGE , Vladimir PRESNYAK , Iain MCFADYEN , Kerry BENENATO , Ellalahewage Sathyajith KUMARASINGHE
IPC: A61K38/20 , A61K9/51 , C07K14/54 , A61K31/7088 , A61K31/7115 , A61K48/00 , C12N15/62 , A61P35/00 , A61K9/00
Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.
-
-
-
-
-
-
-
-
-
Search Results
31
records
(took 0.066 seconds)
